# Study of Antidepressant Efficacy of a Selective, High Affinity Enkephalinergic Agonist in Anxious Major Depressive Disorder (AMDD)

> **NCT00759395** · PHASE2 · COMPLETED · sponsor: **AstraZeneca** · enrollment: 22 (actual)

## Conditions studied

- Anxious Major Depressive Disorder

## Interventions

- **DRUG:** AZD2327
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT00759395
- **Lead sponsor:** AstraZeneca
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2009-01
- **Primary completion:** 2011-10
- **Final completion:** 2011-10
- **Target enrollment:** 22 (ACTUAL)
- **Last updated:** 2012-11-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00759395

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00759395, "Study of Antidepressant Efficacy of a Selective, High Affinity Enkephalinergic Agonist in Anxious Major Depressive Disorder (AMDD)". Retrieved via AI Analytics 2026-07-20 from https://api.ai-analytics.org/clinical/NCT00759395. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*